Business Description
Jiangsu Nhwa Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000CG8
Share Class Description:
SZSE:002262: Class ACompare
Compare
Traded in other countries / regions
002262.China IPO Date
2008-07-23Description
Jiangsu Nhwa Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in manufacturing of APIs and dosages.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 29.9 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.1 | |||||
| Interest Coverage | 247.39 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 19.02 | |||||
| Beneish M-Score | -1.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.7 | |||||
| 3-Year EBITDA Growth Rate | 12.3 | |||||
| 3-Year EPS without NRI Growth Rate | 13 | |||||
| 3-Year FCF Growth Rate | -13.3 | |||||
| 3-Year Book Growth Rate | 16 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 86.17 | |||||
| 9-Day RSI | 77.11 | |||||
| 14-Day RSI | 67.99 | |||||
| 6-1 Month Momentum % | -14.76 | |||||
| 12-1 Month Momentum % | -21.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.65 | |||||
| Quick Ratio | 5.94 | |||||
| Cash Ratio | 4.45 | |||||
| Days Inventory | 166.92 | |||||
| Days Sales Outstanding | 67.26 | |||||
| Days Payable | 72.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.8 | |||||
| Dividend Payout Ratio | 0.18 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| 5-Year Yield-on-Cost % | 3.61 | |||||
| Shareholder Yield % | 0.82 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.18 | |||||
| Operating Margin % | 23.17 | |||||
| Net Margin % | 20.59 | |||||
| FCF Margin % | 10.14 | |||||
| ROE % | 17.19 | |||||
| ROA % | 15.05 | |||||
| ROIC % | 35.32 | |||||
| ROC (Joel Greenblatt) % | 53.07 | |||||
| ROCE % | 19.24 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.59 | |||||
| PE Ratio without NRI | 22.57 | |||||
| Shiller PE Ratio | 39.7 | |||||
| Price-to-Owner-Earnings | 30.06 | |||||
| PEG Ratio | 1.81 | |||||
| PS Ratio | 4.84 | |||||
| PB Ratio | 3.76 | |||||
| Price-to-Tangible-Book | 3.93 | |||||
| Price-to-Free-Cash-Flow | 47.44 | |||||
| Price-to-Operating-Cash-Flow | 28.65 | |||||
| EV-to-EBIT | 17.89 | |||||
| EV-to-EBITDA | 17.89 | |||||
| EV-to-Revenue | 4.16 | |||||
| EV-to-FCF | 40.53 | |||||
| Price-to-Projected-FCF | 2.26 | |||||
| Price-to-DCF (Earnings Based) | 0.76 | |||||
| Price-to-DCF (FCF Based) | 1.52 | |||||
| Price-to-Median-PS-Value | 1.12 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.02 | |||||
| Price-to-Graham-Number | 1.98 | |||||
| Price-to-Net-Current-Asset-Value | 5.52 | |||||
| Price-to-Net-Cash | 9.13 | |||||
| Earnings Yield (Greenblatt) % | 5.59 | |||||
| FCF Yield % | 2.1 | |||||
| Forward Rate of Return (Yacktman) % | 13.44 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers